Tuesday, August 01, 2017 12:43:48 AM
This was a tough, tough PR for me to swallow. Loosely translated..."we don't think the deaths are attributable to the therapy - and people with no hope are improving - but hey, the FDA wants more data before we proceed, so no more patients are allowed into the study for now."
If it were me or one of my love ones, I'd take the scaffold.
I had a significant position in NVIV - shortly after the open, I had sold over half. I mean, what are my choices - sit for months and wait for news while the shorts crucify the stock price? Or should I instead take some off the table and have some cash to work with?
Very depressing day. And I'm not optimistic short term. But I sold to my sleeping point. I can sit on my current position.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM